Fundz

Estrella Immunopharma

California, United States · Biopharma, Biotechnology, Health Care

Estrella Immunopharma is a clinical stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases.

Key facts

Headquarters
California, United States
Employees
Unknown
Industries
Biopharma, Biotechnology, Health Care
Status
Public (ESLA)
Website
www.estrellabio.com

Recent activity at Estrella Immunopharma

  • : Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer
  • : SEC 8-K (5.02):
  • : SEC 8-K (1.01): On January 5, 2026, Estrella Immunopharma, Inc. entered into a Securities Purchase Agreement with an institutional healthcare investor, agreeing to issue 4,063,290 shares of common stock and pre-funded warrants for 1,000,000 shares at a nominal price. The concurrent private placement included common stock purchase warrants for a total of 7,594,935 shares, all part of registered direct offering and private placement with combined purchase prices set at $1.58 and $1.57999 respectively. This transaction was closed on January 6, 2026, generating gross proceeds of approximately $8.0 million for corporate uses. The terms include customary anti-dilution adjustments and ownership limitations for the warrants, emphasizing the strategic considerations in obtaining necessary capital.
  • : SEC 8-K (1.01): On January 5, 2026, Estrella Immunopharma, Inc. entered into a Securities Purchase Agreement with a healthcare-focused institutional investor. This agreement involves a registered direct offering where the Company will issue and sell 4,063,290 shares of common stock at a specified price. The transaction indicates continued capital raising efforts by the Company to support its operations in the healthcare sector. The agreement reflects strategic partnerships with institutional investors, potentially enhancing the Company's financial stability and market presence.
  • : SEC 8-K (8.01): On December 4, 2025, Estrella Immunopharma, Inc. announced the advancement of its STARLIGHT-1 Trial into Phase II following a positive recommendation from the Data and Safety Monitoring Board (DSMB). This decision marks a significant step in the company's clinical development plans and reflects confidence in the trial's outcomes. The press release is attached as Exhibit 99.1 to the filing, providing further details on the implications of this advancement for the company's pipeline and future research directions. The trial's advancement is crucial for Estrella as it seeks to develop innovative treatments in their therapeutic area.
  • : SEC 8-K (8.01): On November 3, 2025, Estrella Immunopharma, Inc. announced the successful completion of the second dose cohort in the Phase I portion of its STARLIGHT-1 clinical trial of EB103. This milestone reflects significant progress in the clinical development of EB103 and is critical for the subsequent phases of the trial. The press release issued alongside this announcement is included as Exhibit 99.1, which highlights the strategic implications for the company's future development plans and potential market impact. The completion of this cohort marks a crucial step in advancing the drug candidate towards potential commercialization. This information was furnished under Item 8.01 and is of importance to security holders regarding the company's operational developments.
  • : Estrella Immunopharma, Inc. receives Buy rating and 12-month price target from D. Boral Capital.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Leadership

  • Cheng Liu, Ph.D., Chief Scientific Officer
  • Cynthia Pussinen, Chief Executive Officer

Verified email and direct lines for Estrella Immunopharma’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Companies similar to Estrella Immunopharma

About Estrella Immunopharma: questions and answers

What does Estrella Immunopharma do?

Estrella Immunopharma is a clinical stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancers and autoimmune diseases.

Where is Estrella Immunopharma headquartered?

Estrella Immunopharma is headquartered in California, United States.

Who leads Estrella Immunopharma?

Cynthia Pussinen is a Chief Executive Officer at Estrella Immunopharma.

What is the latest news on Estrella Immunopharma?

On Oct 26, 2026, Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer

Is Estrella Immunopharma a public company?

Yes. Estrella Immunopharma is publicly traded under the ticker ESLA.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Estrella Immunopharma across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.